Patent Ductus Arteriosus and Its Treatment as Risk Factors for Neonatal and Neurodevelopmental Morbidity
- 1 June 2007
- journal article
- research article
- Published by American Academy of Pediatrics (AAP)
- Vol. 119 (6), 1165-1174
- https://doi.org/10.1542/peds.2006-3124
Abstract
OBJECTIVES. The purpose of this work was to determine whether the reported association between neonatal morbidities and a patent ductus arteriosus is because of the left-to-right patent ductus arteriosus shunt itself, the therapies used to treat it, or the immaturity of the infants who are likely to develop a patent ductus arteriosus. METHODS. A total of 446 infants (<28 weeks' gestation) were treated with the same patent ductus arteriosus care–oriented protocol, and logistic regression analysis was used to examine the effects of several patent ductus arteriosus–related variables (presence of a symptomatic patent ductus arteriosus, the number of indomethacin doses used, the ductus response to indomethacin, and the use of surgical ligation) on the incidence of retinopathy of prematurity, necrotizing enterocolitis, chronic lung disease, death, and neurodevelopmental impairment. RESULTS. Most of the predictive effects that the presence of a patent ductus arteriosus and its treatment had on neonatal morbidity could be accounted for by the infants' immature gestation. Use of surgical ligation, however, was significantly associated with the development of chronic lung disease and was independent of immature gestation, other patent ductus arteriosus–related variables, or other perinatal and neonatal risk factors known to be associated with chronic lung disease. CONCLUSIONS. These findings add to the growing uncertainty about the benefits and risks of surgical ligation during the neonatal period.Keywords
This publication has 41 references indexed in Scilit:
- Treatment to prevent patency of the ductus arteriosus: Beneficial or harmful?The Journal of Pediatrics, 2006
- Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: Further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP)The Journal of Pediatrics, 2006
- Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacinThe Journal of Pediatrics, 1995
- Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosusThe Journal of Pediatrics, 1990
- Localized intestinal perforations after enteral administration of indomethacin in premature infantsThe Journal of Pediatrics, 1985
- Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacinThe Journal of Pediatrics, 1984
- Effects of indomethacin in premature infants with patent ductus arteriosus: Results of a national collaborative studyThe Journal of Pediatrics, 1983
- Continuous wave Doppler ultrasonographic quantitation of patent ductus arteriosus flowThe Journal of Pediatrics, 1982
- Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infantsThe Journal of Pediatrics, 1978
- Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gmThe Journal of Pediatrics, 1978